Year: 2025

DaiichiSankyo-logo

ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial

guidewire_logo_new_2color_h_screen-2022

Guidewire Wins Six XCelent Awards and ‘Luminary’ Distinction in Celent’s Regional Reviews of P&C Policy Administration Systems

SAN MATEO, Calif.--(BUSINESS WIRE)--#XCelent--Guidewire (NYSE: GWRE) announced that Guidewire PolicyCenter has been selected as a winner of six Celent XCelent...

logo-4

2 Day Understanding Pharmacovigilance Regulations in Asia Pacific Training Course: Enhance Your PV Strategy with In-Depth Training on RPPV, PSMF, and RMP Requirements (ONLINE EVENT: June 16-17, 2025) – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Understanding Pharmacovigilance Regulations in APAC Training Course" has been added to ResearchAndMarkets.com's offering. Pharmacovigilance regulations in Asia are...